Interferon-alfa-2b és ribavirin kombinált kezelés krónikus C hepatitisben. 100 Beteg egy évig tartó kezelése során szerzett tapasztalatok. Multicentrikus Tanulmány Munkacsoport.

J. Fehér, G. Lengyel, T. Bálint

Research output: Article

8 Citations (Scopus)

Abstract

It has been established that the long term interferon therapy in patients with chronic hepatitis C is able to produce sustained remission only in about 20 per cent of the cases. According to the newest data the combined interferon and ribavirin therapy significantly increases the remission of patients in naive, non-responder or relapsed cases. Clinical remission was confirmed by enzyme activity of alaninamino transferase (ALT) and HCV-RNA-PCR tests. In order to get exact data of the remission rate and the symptom free period, a prospective multicenter study has been introduced in Hungary. Ten leading hepatologic units have been involved into the trial. Till now the combined therapy with interferon-alfa-2b (3 MU, three times a week) and ribavirin--(1000-1200 mg daily) for one year has been finished in 100 cases with chronic hepatitis C. The mean value of ALT activity decreased near to the normal level, in 58 patients it was in the normal range. Side effects with mild or moderate grades have been found in 31 cases. The interim report of this multicenter study confirm the efficacy of this combined therapy in chronic hepatitis C.

Original languageHungarian
Pages (from-to)1235-1238
Number of pages4
JournalOrvosi hetilap
Volume140
Issue number22
Publication statusPublished - máj. 30 1999

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this